CAS: 83279-38-3; 3-Chloro-4-(Trifluoromethyl)Benzaldehyde

上下游产品

3-氯-4-(三氟甲基)苄基乙醇 (3-Chloro-4-(Trifluoromethyl)Phenyl)Methanol 948014-51-5
3-氯-4-三氟甲基苯腈 3-Chloro-4-(Trifluoromethyl)Benzonitrile 1092460-79-1
4-溴-2-氯三氟甲苯 4-Bromo-2-Chloro-1-(Trifluoromethyl)Benzene 467435-07-0

3-氯-4-三氟甲基苯腈置于二异丁基氢化铝,盐酸,水体系中,用 四氢呋喃,甲苯 作为反应溶剂,化学反应 5.5H,以74%的收率获得产物4-氨基-2,3-二氟苯腈
参考文献:Trpv1 Antagonists
标题:Trpv1 Antagonists
摘要:公式(i)中r1,R2,R4和w所定义的化合物是trpv 1拮抗剂,具有中枢神经系统渗透性.还公开了包含这类化合物的组合物以及使用这类化合物和组合物治疗疾病和疾病的方法.

专利信息

专利号:US-4681891-A
优先权日:1984-11-27
标 题 :Dihydro-2,6-dimethyl pyridines, formulations and method of use for treating angina pectoris, high blood pressure or disturbances of cerebral or peripheral blood flow
发明人：SCHOENAFINGER KARL; BOHN HELMUT; MARTORANA PIERO; NITZ ROLF-EBERHARD
权利人:CASSELLA FARBWERKE MAINKUR AG
摘要:1,4-dihydropyridines of the formula I (I) wherein R1 denotes optionally substituted phenyl, pyridyl or thienyl, R2 denotes optionally substituted oxadiazolyl, thiadiazolyl or thiazolyl and R3 denotes hydrogen or -COOH, their preparation by a modified Hantzsch synthesis and their use as a calcium-agonist in pharmacy.

专利号:US-9446047-B2
优先权日:2013-09-10
标 题 :Substituted 2,3-dihydro-1H-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis
发明人：VANKAYALAPATI HARIPRASAD; YERRAMREDDY VENKATAKRISHNAREDDY
权利人:ARRIEN PHARMACEUTICALS LLC
摘要:The present invention is directed to compounds, their synthesis, and their use as antagonists, inverse agonists, modulators and or inhibitors of the Retinoic acid-related orphan nuclear receptor γt (RORγt)/RORγ. The compounds of the present invention are useful for modulating RORγt)/RORγ activity and for treating diseases or conditions mediated by RORγt)/RORγ such as for example, disease states associated with immunopathology of human autoimmune diseases such as Multiple Sclerosis (MS), Rheumatoid Arthritis (RA), Inflammatory Colitis, Psoriasis, COPD, Pain, Obesity, Diabetes, Dyslipidemia, Osteoporosis, Asthma, Neurodegenerative diseases and Cancer.